Cargando…

Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection

BACKGROUND: Earlier kinetics of serum HCV core antigen (HCVcAg) and its predictive value on sustained virological response (SVR) were investigated in patients with genotype 1 HCV infection during antiviral treatment. METHODS: In a multi-centered, randomized and positive drug-controlled phase IIb cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Bo, Yang, Rui-Feng, Xie, Qing, Shang, Jia, Kong, Fan-Yun, Zhang, Hai-Ying, Rao, Hui-Ying, Jin, Qian, Cong, Xu, Liu, Yun-Ye, Kang, Yi, Wei, Lai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995626/
https://www.ncbi.nlm.nih.gov/pubmed/24625322
http://dx.doi.org/10.1186/1471-230X-14-47
_version_ 1782312902413254656
author Feng, Bo
Yang, Rui-Feng
Xie, Qing
Shang, Jia
Kong, Fan-Yun
Zhang, Hai-Ying
Rao, Hui-Ying
Jin, Qian
Cong, Xu
Liu, Yun-Ye
Kang, Yi
Wei, Lai
author_facet Feng, Bo
Yang, Rui-Feng
Xie, Qing
Shang, Jia
Kong, Fan-Yun
Zhang, Hai-Ying
Rao, Hui-Ying
Jin, Qian
Cong, Xu
Liu, Yun-Ye
Kang, Yi
Wei, Lai
author_sort Feng, Bo
collection PubMed
description BACKGROUND: Earlier kinetics of serum HCV core antigen (HCVcAg) and its predictive value on sustained virological response (SVR) were investigated in patients with genotype 1 HCV infection during antiviral treatment. METHODS: In a multi-centered, randomized and positive drug-controlled phase IIb clinical trial on type Y peginterferon α-2b ( NCT01140997), forty-eight CHC patients who participated in pharmacokinetics were randomly divided into 4 cohorts and treated with PegIFNα (type Y peginterferon α-2b 90 μg, 135 μg, 180 μg and PegIFNα-2a 180 μg, respectively, once a week) and ribavirin (< 75 kg, 1000 mg daily and ≥ 75 kg, 1200 mg daily) for 48 weeks, and then followed up for 24 weeks. 32 patients infected with genotype 1 HCV and completed the whole process were included in this study. HCV RNAs were detected at baseline, and weeks 4, 12, 24, 48 and 72 using Cobas TaqMan. ARCHITECT HCVcAg was performed at 24, 48, 72, 96, 120 and 144 h in addition to the above time points. The receiver operating curves (ROCs) were performed to study the predictive values of HCVcAg decline on SVR. RESULTS: Following antiviral treatment, serum HCVcAg levels rapidly declined within the first week and correlated well with corresponding HCV RNA at baseline, weeks 4, 12, 24, 48 and 72 (r(s) = 0.969, 0.928, 0.999, 0.983, 0.985 and 0.946, respectively, P < 0.001). All of the areas under the receiver operating curves (AUROCs) were more than 0.80 and showed good predictive power on SVR at 24, 48, 72, 96, 120 and 144 h. The144 h was the best predictive time point of HCVcAg decline on SVR because of its largest AUROC (more than 0.90). CONCLUSIONS: Early kinetics of serum HCVcAg predicts SVR very well in genotype 1 CHC patients during antiviral treatment, and its reduction value at 144 h is an earlier and stronger predictor on SVR than rapid virological response and early virological response. (TRN: NCT01140997).
format Online
Article
Text
id pubmed-3995626
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39956262014-04-23 Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection Feng, Bo Yang, Rui-Feng Xie, Qing Shang, Jia Kong, Fan-Yun Zhang, Hai-Ying Rao, Hui-Ying Jin, Qian Cong, Xu Liu, Yun-Ye Kang, Yi Wei, Lai BMC Gastroenterol Research Article BACKGROUND: Earlier kinetics of serum HCV core antigen (HCVcAg) and its predictive value on sustained virological response (SVR) were investigated in patients with genotype 1 HCV infection during antiviral treatment. METHODS: In a multi-centered, randomized and positive drug-controlled phase IIb clinical trial on type Y peginterferon α-2b ( NCT01140997), forty-eight CHC patients who participated in pharmacokinetics were randomly divided into 4 cohorts and treated with PegIFNα (type Y peginterferon α-2b 90 μg, 135 μg, 180 μg and PegIFNα-2a 180 μg, respectively, once a week) and ribavirin (< 75 kg, 1000 mg daily and ≥ 75 kg, 1200 mg daily) for 48 weeks, and then followed up for 24 weeks. 32 patients infected with genotype 1 HCV and completed the whole process were included in this study. HCV RNAs were detected at baseline, and weeks 4, 12, 24, 48 and 72 using Cobas TaqMan. ARCHITECT HCVcAg was performed at 24, 48, 72, 96, 120 and 144 h in addition to the above time points. The receiver operating curves (ROCs) were performed to study the predictive values of HCVcAg decline on SVR. RESULTS: Following antiviral treatment, serum HCVcAg levels rapidly declined within the first week and correlated well with corresponding HCV RNA at baseline, weeks 4, 12, 24, 48 and 72 (r(s) = 0.969, 0.928, 0.999, 0.983, 0.985 and 0.946, respectively, P < 0.001). All of the areas under the receiver operating curves (AUROCs) were more than 0.80 and showed good predictive power on SVR at 24, 48, 72, 96, 120 and 144 h. The144 h was the best predictive time point of HCVcAg decline on SVR because of its largest AUROC (more than 0.90). CONCLUSIONS: Early kinetics of serum HCVcAg predicts SVR very well in genotype 1 CHC patients during antiviral treatment, and its reduction value at 144 h is an earlier and stronger predictor on SVR than rapid virological response and early virological response. (TRN: NCT01140997). BioMed Central 2014-03-13 /pmc/articles/PMC3995626/ /pubmed/24625322 http://dx.doi.org/10.1186/1471-230X-14-47 Text en Copyright © 2014 Feng et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Feng, Bo
Yang, Rui-Feng
Xie, Qing
Shang, Jia
Kong, Fan-Yun
Zhang, Hai-Ying
Rao, Hui-Ying
Jin, Qian
Cong, Xu
Liu, Yun-Ye
Kang, Yi
Wei, Lai
Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection
title Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection
title_full Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection
title_fullStr Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection
title_full_unstemmed Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection
title_short Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection
title_sort hepatitis c virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 hcv infection
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995626/
https://www.ncbi.nlm.nih.gov/pubmed/24625322
http://dx.doi.org/10.1186/1471-230X-14-47
work_keys_str_mv AT fengbo hepatitiscviruscoreantigenanearlierandstrongerpredictoronsustainedvirologicalresponseinpatientswithgenotype1hcvinfection
AT yangruifeng hepatitiscviruscoreantigenanearlierandstrongerpredictoronsustainedvirologicalresponseinpatientswithgenotype1hcvinfection
AT xieqing hepatitiscviruscoreantigenanearlierandstrongerpredictoronsustainedvirologicalresponseinpatientswithgenotype1hcvinfection
AT shangjia hepatitiscviruscoreantigenanearlierandstrongerpredictoronsustainedvirologicalresponseinpatientswithgenotype1hcvinfection
AT kongfanyun hepatitiscviruscoreantigenanearlierandstrongerpredictoronsustainedvirologicalresponseinpatientswithgenotype1hcvinfection
AT zhanghaiying hepatitiscviruscoreantigenanearlierandstrongerpredictoronsustainedvirologicalresponseinpatientswithgenotype1hcvinfection
AT raohuiying hepatitiscviruscoreantigenanearlierandstrongerpredictoronsustainedvirologicalresponseinpatientswithgenotype1hcvinfection
AT jinqian hepatitiscviruscoreantigenanearlierandstrongerpredictoronsustainedvirologicalresponseinpatientswithgenotype1hcvinfection
AT congxu hepatitiscviruscoreantigenanearlierandstrongerpredictoronsustainedvirologicalresponseinpatientswithgenotype1hcvinfection
AT liuyunye hepatitiscviruscoreantigenanearlierandstrongerpredictoronsustainedvirologicalresponseinpatientswithgenotype1hcvinfection
AT kangyi hepatitiscviruscoreantigenanearlierandstrongerpredictoronsustainedvirologicalresponseinpatientswithgenotype1hcvinfection
AT weilai hepatitiscviruscoreantigenanearlierandstrongerpredictoronsustainedvirologicalresponseinpatientswithgenotype1hcvinfection